BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32483448)

  • 1. CDK12 and PAK2 as novel therapeutic targets for human gastric cancer.
    Liu H; Shin SH; Chen H; Liu T; Li Z; Hu Y; Liu F; Zhang C; Kim DJ; Liu K; Dong Z
    Theranostics; 2020; 10(14):6201-6215. PubMed ID: 32483448
    [No Abstract]   [Full Text] [Related]  

  • 2. Activation of P21-activated protein kinase 2 is an independent prognostic predictor for patients with gastric cancer.
    Gao C; Ma T; Pang L; Xie R
    Diagn Pathol; 2014 Mar; 9():55. PubMed ID: 24621074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8
    Ji J; Zhou C; Wu J; Cai Q; Shi M; Zhang H; Yu Y; Zhu Z; Zhang J
    Int J Med Sci; 2019; 16(8):1142-1148. PubMed ID: 31523177
    [No Abstract]   [Full Text] [Related]  

  • 4. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
    Choi HJ; Jin S; Cho H; Won HY; An HW; Jeong GY; Park YU; Kim HY; Park MK; Son T; Min KW; Jang KS; Oh YH; Lee JY; Kong G
    EMBO Rep; 2019 Oct; 20(10):e48058. PubMed ID: 31468695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration.
    Yang B; Chen J; Teng Y
    J Immunol Res; 2021; 2021():6645885. PubMed ID: 33628849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome.
    Liu M; Fan H; Li T; Sihong L; Qiao S; Bi J
    Pathol Res Pract; 2020 Jul; 216(7):152962. PubMed ID: 32534699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
    Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
    Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
    Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA miR-4779 suppresses tumor growth by inducing apoptosis and cell cycle arrest through direct targeting of PAK2 and CCND3.
    Koo KH; Kwon H
    Cell Death Dis; 2018 Jan; 9(2):77. PubMed ID: 29362401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1.
    Liu F; Li X; Wang C; Cai X; Du Z; Xu H; Li F
    Int J Cancer; 2009 Dec; 125(11):2511-9. PubMed ID: 19610058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling.
    Gan J; Ke X; Jiang J; Dong H; Yao Z; Lin Y; Lin W; Wu X; Yan S; Zhuang Y; Chu WK; Cai R; Zhang X; Cheung HS; Block NL; Pang CP; Schally AV; Zhang H
    Proc Natl Acad Sci U S A; 2016 Dec; 113(51):14745-14750. PubMed ID: 27930339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK12: an emerging therapeutic target for cancer.
    Lui GYL; Grandori C; Kemp CJ
    J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma.
    Chung EY; Mai Y; Shah UA; Wei Y; Ishida E; Kataoka K; Ren X; Pradhan K; Bartholdy B; Wei X; Zou Y; Zhang J; Ogawa S; Steidl U; Zang X; Verma A; Janakiram M; Ye BH
    Clin Cancer Res; 2019 Jun; 25(12):3589-3601. PubMed ID: 30862694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.
    Siekmann IK; Dierck K; Prall S; Klokow M; Strauss J; Buhs S; Wrzeszcz A; Bockmayr M; Beck F; Trochimiuk M; Gottschling K; Martens V; Khosh-Naucke M; Gerull H; Müller J; Behrmann L; Blohm M; Zahedi RP; Jeremias I; Sickmann A; Nollau P; Horstmann MA
    Blood Adv; 2018 Oct; 2(19):2554-2567. PubMed ID: 30301811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK12 orchestrates super-enhancer-associated CCDC137 transcription to direct hepatic metastasis in colorectal cancer.
    Dai W; Wu J; Peng X; Hou W; Huang H; Cheng Q; Liu Z; Luyten W; Schoofs L; Zhou J; Liu S
    Clin Transl Med; 2022 Oct; 12(10):e1087. PubMed ID: 36254394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
    Lu J; Li G; He K; Jiang W; Xu C; Li Z; Wang H; Wang W; Wang H; Teng X; Teng L
    J Transl Med; 2015 Feb; 13():42. PubMed ID: 25638174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PAK1 with the Small Molecule Drug AK963/40708899 Suppresses Gastric Cancer Cell Proliferation and Invasion by Downregulation of PAK1 Activity and PAK1-Related Signaling Pathways.
    Zhou Y; Zhang J; Wang J; Cheng MS; Zhao DM; Li F
    Anat Rec (Hoboken); 2019 Sep; 302(9):1571-1579. PubMed ID: 30773850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
    Wang C; Wang H; Lieftink C; du Chatinier A; Gao D; Jin G; Jin H; Beijersbergen RL; Qin W; Bernards R
    Gut; 2020 Apr; 69(4):727-736. PubMed ID: 31519701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.